topstockalerts
Oct 29, 1:54 AM
Guggenheim Securities reiterated its Buy rating on LB Pharmaceuticals and named it a top investment idea, maintaining an
$80 price target, implying approximately 102% upside from
$39.64. The broker cited promising clinical data for experimental schizophrenia drug LB-102 ahead of pivotal Phase 3 results expected in H1 2027.
In the Phase 2 NOVA-1 trial, extrapyramidal side effects, including akathisia, ranged from 0.9% to 5.6%. Preclinical brain-mapping data suggest LB-102 primarily targets regions associated with psychosis while largely sparing motor regions, potentially explaining its lower movement-related side effects.
The upcoming NOVA-2 trial will evaluate 50 mg and 100 mg doses in approximately 460 patients across 25 U.S. sites. The FDA has indicated that NOVA-1 could count as one of the two required pivotal studies. Guggenheim estimates a 75% probability of success in schizophrenia and 45% for bipolar depression.
$LBRX
